Numerous PCSK9 mutations have been identified in all three domains that confer a gain-of-function (GOF), resulting in an autosomal-dominant form of familial hypercholesterolemia (FH) (Abifadel et al., 2009; Dron and Hegele, 2017). Here, PCSK9 is linked to familial hyperaldosteronism.